Kwak HJ - Search Results

1

Bortezomib attenuates palmitic acid-induced ER stress, inflammation and insulin resistance in myotubes via AMPK dependent mechanism.

Kwak HJ, Choi HE, Jang J, Park SK, Bae YA, Cheon HG. Kwak HJ, et al. Cell Signal. 2016 Aug;28(8):788-97. doi: 10.1016/j.cellsig.2016.03.015. Epub 2016 Apr 2. Cell Signal. 2016. PMID: 27049873

2

Roflumilast inhibits lipopolysaccharide-induced inflammatory mediators via suppression of nuclear factor-kappaB, p38 mitogen-activated protein kinase, and c-Jun NH2-terminal kinase activation.

Kwak HJ, Song JS, Heo JY, Yang SD, Nam JY, Cheon HG. Kwak HJ, et al. J Pharmacol Exp Ther. 2005 Dec;315(3):1188-95. doi: 10.1124/jpet.105.092056. Epub 2005 Aug 26. J Pharmacol Exp Ther. 2005. PMID: 16126838

3

The inhibitory effects of roflumilast on lipopolysaccharide-induced nitric oxide production in RAW264.7 cells are mediated by heme oxygenase-1 and its product carbon monoxide.

Kwak HJ, Song JS, No ZS, Song JH, Yang SD, Cheon HG. Kwak HJ, et al. Inflamm Res. 2005 Dec;54(12):508-13. doi: 10.1007/s00011-005-1386-1. Inflamm Res. 2005. PMID: 16389572

4

15d-PGJ2 stimulates HO-1 expression through p38 MAP kinase and Nrf-2 pathway in rat vascular smooth muscle cells.

Lim HJ, Lee KS, Lee S, Park JH, Choi HE, Go SH, Kwak HJ, Park HY. Lim HJ, et al. Among authors: kwak hj. Toxicol Appl Pharmacol. 2007 Aug 15;223(1):20-7. doi: 10.1016/j.taap.2007.04.019. Epub 2007 Jun 8. Toxicol Appl Pharmacol. 2007. PMID: 17631927

5

PDE4 inhibitor, roflumilast protects cardiomyocytes against NO-induced apoptosis via activation of PKA and Epac dual pathways.

Kwak HJ, Park KM, Choi HE, Chung KS, Lim HJ, Park HY. Kwak HJ, et al. Cell Signal. 2008 May;20(5):803-14. doi: 10.1016/j.cellsig.2007.12.011. Epub 2007 Dec 28. Cell Signal. 2008. PMID: 18276108

6

Protective effects of pyrrolidine dithiocarbamate against airway inflammation in the ovalbumin-induced mouse model.

Kwak HJ, Song JS, Heo JY, Yang SD, Nam JY, Cho YS, Cheon HG. Kwak HJ, et al. Eur J Pharmacol. 2008 Aug 20;590(1-3):355-62. doi: 10.1016/j.ejphar.2008.06.043. Epub 2008 Jun 15. Eur J Pharmacol. 2008. PMID: 18601919

7

Protective mechanisms of NO preconditioning against NO-induced apoptosis in H9c2 cells: role of PKC and COX-2.

Kwak HJ, Park KM, Choi HE, Park HY. Kwak HJ, et al. Free Radic Res. 2009 Aug;43(8):744-52. doi: 10.1080/10715760903040602. Free Radic Res. 2009. PMID: 19591013

8

The cardioprotective effects of zileuton, a 5-lipoxygenase inhibitor, are mediated by COX-2 via activation of PKC delta.

Kwak HJ, Park KM, Choi HE, Lim HJ, Park JH, Park HY. Kwak HJ, et al. Cell Signal. 2010 Jan;22(1):80-7. doi: 10.1016/j.cellsig.2009.09.014. Epub 2009 Sep 22. Cell Signal. 2010. PMID: 19781629

9

Discovery of a novel orally active PDE-4 inhibitor effective in an ovalbumin-induced asthma murine model.

Kwak HJ, Nam JY, Song JS, No Z, Yang SD, Cheon HG. Kwak HJ, et al. Eur J Pharmacol. 2012 Jun 15;685(1-3):141-8. doi: 10.1016/j.ejphar.2012.04.016. Epub 2012 Apr 20. Eur J Pharmacol. 2012. PMID: 22554769

10

The role of prolyl hydroxylase domain protein (PHD) during rosiglitazone-induced adipocyte differentiation.

Kim J, Kwak HJ, Cha JY, Jeong YS, Rhee SD, Cheon HG. Kim J, et al. Among authors: kwak hj. J Biol Chem. 2014 Jan 31;289(5):2755-64. doi: 10.1074/jbc.M113.493650. Epub 2013 Dec 12. J Biol Chem. 2014. PMID: 24338020 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

301 results

Search Page

Filters